Andrew A Wolff Net Worth

The estimated Net Worth of Andrew A Wolff is at least $2.31 million dollars as of 11 March 2015. Andrew Wolff owns over 21,875 units of Cytokinetics Inc stock worth over $2,314,046 and over the last 20 years Andrew sold CYTK stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Wolff CYTK stock SEC Form 4 insiders trading

Andrew has made over 1 trades of the Cytokinetics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Andrew exercised 21,875 units of CYTK stock worth $137,813 on 11 March 2015.

The largest trade Andrew's ever made was exercising 21,875 units of Cytokinetics Inc stock on 11 March 2015 worth over $137,813. On average, Andrew trades about 1,287 units every 0 days since 2004. As of 11 March 2015 Andrew still owns at least 43,036 units of Cytokinetics Inc stock.

You can see the complete history of Andrew Wolff stock trades at the bottom of the page.

What's Andrew Wolff's mailing address?

Andrew's mailing address filed with the SEC is 280, East Grand Avenue, South San Francisco, San Mateo County, California, 94080, United States.

Insiders trading at Cytokinetics Inc

Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi... et Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.

What does Cytokinetics Inc do?

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Complete history of Andrew Wolff stock trades at Cytokinetics Inc

Cytokinetics Inc executives and stock owners

Cytokinetics Inc executives and other stock owners filed with the SEC include:

• Robert Blum,
  President, Chief Executive Officer, Director
• Fady Malik,
  Executive Vice President - Research and Development
• Mark Schlossberg,
  Senior Vice President, General Counsel, Secretary
• Ching Jaw,
  Chief Financial Officer, Senior Vice President
• David Cragg,
  Chief Human Resource Officer, Chief Administrative Officer
• Robert I. Blum,
  CEO, Pres & Director
• Dr. Fady Ibraham Malik,
  Exec. VP of R&D
• Mark A. Schlossberg,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Ching W. Jaw,
  Sr. VP & CFO
• David W. Cragg,
  Chief HR & Admin. Officer
• Leonard Patrick Gage,
  Independent Chairman of the Board
• Wendall Wierenga,
  Independent Director
• B. Lynne Parshall,
  Independent Director
• John Henderson,
  Independent Director
• Santo Costa,
  Independent Director
• Sandford Smith,
  Independent Director
• Edward Kaye,
  Independent Director
• Robert Califf,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Diane Weiser,
  IR Contact Officer
• Robert Wong,
  Chief Accounting Officer, Vice President
• Kari K. Loeser J.D.,
  VP & Chief Compliance Officer
• Robert Wong,
  VP & Chief Accounting Officer
• Jeff Lotz,
  VP of Sales & Operations
• Dr. James A. Spudich Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Bradley Paul Morgan,
  SVP Drug Discovery & Early Dev
• Caryn Gordon Mc Dowell,
  GC & Chief Compliance Officer
• Elisabeth Schnieders,
  Sr. VP, Business Development
• L Patrick Gage,
  Director
• Bonnie Charpentier,
  SVP Regulatory & Compliance
• Robert Arthur Harrington,
  Director
• Associates Vi Lp Srb,
  10% owner
• Sung Lee,
  EVP, Chief Financial Officer
• Peter S Roddy,
  SVP Finance & CAO
• Muna Bhanji,
  Director
• Michael Rabson,
  SVP Business Dev/Legal & GC
• A Grant Iii Heidrich,
  Director
• Mark Mcdade,
  Director
• Brett A Pletcher,
  EVP, Chief Legal Officer
• Sharon Barbari,
  Sr. VP, Finance & CFO
• Charles J Homcy,
  Director
• James H Sabry,
  President and CEO
• David J Jr Morgans,
  SVP-Drug Discovery and Dev
• James A Spudich,
  Director
• Michael Schmertzler,
  Director
• Jay K Trautman,
  VP, Technology
• Stephen M Dow,
  Director
• Denise Gilbert,
  Director
• Capital Ltd Portfolio Servi...,
  
• Suisse First Boston/Credit ...,
  
• John Vdomenik Stephen Lbayl...,
  
• William J Rutter,
  Director
• Ixmayfield Ix Management Ll...,
  
• Rosen Vii Affiliates Fund L...,
  10% owner
• Associates Vii Lp Srb,
  10% owner
• Associates Viii Lp Srb,
  10% owner
• Rosen Viii Affiliates Fund ...,
  10% owner
• Rosen Fund Viii Lp Sevin,
  10% owner
• Rosen Fund Vi Lp Sevin,
  10% owner
• Rosen Fund Vii Lp Sevin,
  10% owner
• Rosen Vi Affiliates Fund Lp...,
  10% owner
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Andrew Callos,
  EVP, Chief Commercial Officer